Health TrialsbyHealthPanel

Prosthetic Joint Infection : Lessons From Deceased Patients in Critical Care.

ConditionsOsteoarticular InfectionsIntensive Care PatientsProsthetic Joint Infection
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorAssistance Publique - Hôpitaux de Paris

About this trial

This is an observational, retrospective, multicenter study based on the use of demographic, clinical and biological data from deceased patients admitted between 2018 and 2022 to critical care with a principal or associated diagnosis of joint prosthesis infection.

Data from this study will be combined with that from the OASIS study (APHP241174/ ID-RCB: 2024-A01769-38) concerning osteoarticular sepsis on prosthetic material in critical care of living patients.

The aim of this study is to improve our knowledge of the profile, care trajectories and outcomes of patients hospitalized in critical care in the context of osteoarticular material sepsis.

The results of the study could help identify at-risk populations and improve management strategies for patients with osteoarticular sepsis.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patient aged 18 years or older.

Hospitalization in critical care (intensive care unit or continuing care unit) between 2018 and 2022, lasting at least 48 hours, with a prosthetic joint infection (hip, knee, or shoulder prosthesis infection) as the primary or associated diagnosis.

Deceased patient who had not refused data processing.

Disqualifiers

Infection involving osteosynthesis material

Infection involving spinal instrumentation

Patient with multiple infected prostheses

Recurrence of prosthetic infection with the same microorganism as a previous episode

Trial population

Critical care patients (intensive care and continuing care), admitted between 2018 and 2022 with a principal or associated diagnosis of joint prosthesis infection, who have since died.

Trial design

Design model

Cohort

Time perspective

Retrospective

Treatments tested in this trial

  • Global cohort

    Other intervention

    All deceased patients admitted to intensive care during the study period and satisfying the eligibility criteria.

Treatment groups

No treatment groups listed

Trial outcomes

Primary outcomes

1

Epidemiological description of deceased patients

Demographic data, medical history, history of Periprosthetic Joint Infection (timing, diagnosis, surgery, antibiotics), data in intensive care unit (leng of stay, organ failure, drugs and mechanical support, biological data) and outcome (time of death within 2 years after admission to Intensive Care Units).

Time frame
2 years

Secondary outcomes

1

Composite endpoint reflecting poor clinical outcome

* Mortality, measured in critical care, at 30 days, 1 year and 2 years. * Therapeutic failure at 2 years, defined as mechanical or septic failure. * Functional failure at 2 years, defined as failure to resume walking and usual activities, to return home, or to regain autonomy.

Time frame
2 years
2

Mortality at 2 years

Time frame
2 years
3

Epidemiological description based on the number (n) and proportion (%) of bacterial strains found in samples collected during the operation.

Special focus on: Gram-positive bacteria (Staphylococcus, Streptococcus, Enterococcus), Gram-negative bacteria (Enterobacteriacea, Pseudmononas), slow-growing bacteria (Cutibacterium, Corynenbacteria), yeasts; resistance mechanisms (meticillin, rifampicin, quinolone, glycopeptide, ESBL, carbapenem).

Time frame
2 years

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Assistance Publique - Hôpitaux de Paris

Lead sponsor

Source ClinicalTrials.gov
Apply now